57 results about "Beta globulins" patented technology

The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy chain transgene in the foregoing animals comprises a human constant region gene segment comprising exons encoding the desired heavy chain isotype, operably linked to switch segments from a constant region of a different heavy chain isotype, i.e., a non-cognate switch region. Said additional constant region segment comprises a switch region and human constant region coding segment, wherein the constant region coding segment is operably linked to a switch region that it is not normally associated with, i.e., a non-cognate switch region. In the transgenes of the invention, the non-cognate switch region may be a switch region from a different species than the constant region coding segment. The switch region and membrane exons of the invention may comprise a human gamma-2 constant region and the secreted constant region exons are from a human gamma-1 or a human gamma-4 constant region.

The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and / or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.

The present invention provides methods for the quantification of human, human chimeric, humanized antibodies or fragments thereof without the use of target specific molecules. More specifically, the present invention relates to a quantitative assay comprising the step of blocking the non-specific binding sites of a capture agent with a blocking buffer comprising a non-human mammalian globulin such as bovine gamma globulin (BGG).

The invention discloses a method for separating [alpha]-lactalbumin and [beta]-lactoglobulin. The present invention relates to a method for providing an alpha-lactalbumin fraction and a beta-lactoglobulin fraction from a whey material obtained from milk, the method comprising the steps of: (i) providing the whey material; (ii) contacting the whey material with a chromatographic support allowing beta-lactoglobulin to be retained by the chromatographic support; (iii) obtaining a permeate fraction from the chromatographic support comprising the alpha-lactalbumin fraction; (iv) optionally washing the chromatographic support; and (v) obtaining a retentate fraction from the chromatographic support comprising the beta-lactoglobulin fraction; wherein the whey material provided in step (i) has been depleted, or substantially depleted from at least one whey protein, such as at least 2 whey proteins, e.g. at least 3 whey proteins.

The invention discloses a cell cryopreservation medium for dendritic cells. An effective amount of cryoprotective agents, cell stabilizers and anti-setting agents are added into RPMI-1640 culture medium and uniformly mixed to form the cell cryopreservation medium for the dendritic cells. The cryoprotective agent is dimethyl sulfoxide, and the cell stabilizer is human gamma globulin; the anti-setting agent is poly-L-lysine, and the molecular weight range of the poly-L-lysine is 30000 to 70000; and the volume percentage concentration of the dimethyl sulfoxide is 1 to 3 percent. When used for cryopreserving DCs, the cell cryopreservation medium disclosed by the invention can ensure the cryopreservation revival rate and immunocompetence of the DCs, and the cryopreservation revival rate and the immunocompetence are not significantly decreased within one year of cryopreservation; the human gamma globulin as the cell stabilizer can maintain the immunocompetence of the DCs; the poly-L-lysine as the anti-settling agent can prevent the human gamma globulin from settling to the bottom of the cell cryopreservation medium in the process of storage, and moreover, the poly-L-lysine has part of the effect of the cryoprotective agent, and can also help to maintain the immunocompetence of the DCs.

The present invention provides new compositions and methods useful for the treatment and potential cure of beta-globinopathies such as sickle cell disease and beta-thalassemia by inhibiting the expression and / or activity of RIOK3.